Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3456-3461

  Tomei, Sara ^a,b   Adams, Sharon ^b   Uccellini, Lorenzo ^b,c   Bedognetti, Davide ^b   De Giorgi, Valeria ^b   Erdenebileg, Narnygerel ^b   Ascierto, Maria Libera ^b,d,e   Reinboth, Jennifer ^b,f,g   Liu, Qiuzhen ^b   Bevilacqua, Generoso ^a   Wang, Ena ^b   Mazzanti, Chiara ^a   Marincola, Francesco M ^b  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g GENELUX CORPORATION   (United States)

Author keywords

HRAS; Melanoma; Polymorphism; rs112587690; rs12628

Indexed keywords

INTERLEUKIN 2; HRAS PROTEIN, HUMAN; PROTEIN P21;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CONTROLLED STUDY; CUTANEOUS MELANOMA; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; NORTH AMERICA; ONCOGENE H RAS; POPULATION GENETICS; POPULATION RISK; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; MELANOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SKIN TUMOR;

EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MELANOMA; NORTH AMERICA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS P21(RAS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SKIN NEOPLASMS;

EID: 84880302935     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0255-3     Document Type: Article

References (20)

1. Sober AJ, Lew RA, Koh HK, Barnhill RL. Epidemiology of cutaneous melanoma. An update. Dermatol Clin. 1991;9(4):617-29.
2. Urist MM, Karnell LH. The national cancer data base. Report on melanoma. Cancer. 1994;74(2):782-8.
3. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, et al. Main roads to melanoma. J Transl Med. 2009;7:86. doi: 10.1186/1479-5876-7-86.
4. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006;5(8):928-32.
5. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol. 2002;192(2):125-30. doi: 10.1002/jcp.10109.
6. Liwo A, Gibson KD, Scheraga HA, Brandt-Rauf PW, Monaco R, Pincus MR. Comparison of the low energy conformations of an oncogenic and a non-oncogenic p21 protein, neither of which binds GTP or GDP. J Protein Chem. 1994;13(2):237-51.
7. Monaco R, Chen JM, Chung D, Brandt-Rauf P, Pincus MR. Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein. J Protein Chem. 1995;14(6):457-66.
8. Noonan T, Brown N, Dudycz L, Wright G. Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins. J Med Chem. 1991;34(4):1302-7.
9. Furth ME, Aldrich TH, Cordon-Cardo C. Expression of ras proto-oncogene proteins in normal human tissues. Oncogene. 1987;1(1):47-58.
10. Pethe V, Shekhar PV. Estrogen inducibility of c-Ha-ras transcription in breast cancer cells. Identification of functional estrogen-responsive transcriptional regulatory elements in exon 1/intron 1 of the c-Ha-ras gene. J Biol Chem. 1999;274(43):30969-78.
11. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature. 1982;300(5894):762-5.
12. Johne A, Roots I, Brockmoller J. A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(1):68-70.
13. Zhang Y, Jin M, Liu B, Ma X, Yao K, Li Q, et al. Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in China. BMC Cancer. 2008;8:256. doi: 10.1186/1471-2407-8-256.
14. Catela Ivkovic T, Loncar B, Spaventi R, Kapitanovic S. Association of H-ras polymorphisms and susceptibility to sporadic colon cancer. Int J Oncol. 2009;35(5):1169-73.
15. Pandith AA, Shah ZA, Khan NP, Baba KM, Wani MS, Siddiqi MA. HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population. Urol Oncol. 2011. doi: 10.1016/j.urolonc.2011.03.004.
16. Spivey T, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q et al. The stable aspects of melanoma genetics. BMC Genom. 2012;13(1):156.
17. Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat. 2006;27(8):736-41. doi: 10.1002/humu.20381.
18. Papadakis EN, Dokianakis DN, Spandidos DA. Genetic analysis of H-ras intron-1 polymorphic and variable tandem repeat regions in human breast cancer. Int J Biol Markers. 2003;18(3):195-9.
19. Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010;8:4. doi: 10.1186/1479-5876-8-4.
20. Kruglyak L. The road to genome-wide association studies. Nat Rev Genet. 2008;9(4):314-8. doi: 10.1038/nrg2316.